SPOTLIGHT: Antisoma in licensing talks

The UK's Antisoma is sounding bullish about its licensing prospects for its flagship drug, AS1404, a potential blockbuster cancer therapy. Antisoma chief Glyn Edwards says that he's in talks with a number of big pharma companies, but couldn't say exactly when a deal might be completed. Antisoma also announced positive Phase II data for AS1404 today. Report

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.